⌘K
Loading ticker…
Amylyx Pharmaceuticals, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) has a 3-month relative strength percentile of 82 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 69. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 6.6%, relative volume 2.27×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 82, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
AMLX is in a stage 2 uptrend, week 2. Currently in a 48-day base; basing ADR 5.5% (broad 6.1%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 17.1% / 25.0%.
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
AMLX is held by 6 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $43M notional. Top 3 carry $87M.
Top 6 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $43M |
| IWMiShares Russell 2000 ETF | 0.04% | $31M |
| VXFVanguard Extended Market ETF | 0.02% | $13M |
| IWOiShares Russell 2000 Growth ETF | 0.07% | $8M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | 1.79% | $5M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $2M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AMLX Jan avg: 7.40% median: 7.38% win: 75% σ: 8.94% n: 4 2022-04-12 → 2026-05-29 | AMLX Feb avg: 0.67% median: -1.99% win: 50% σ: 13.91% n: 4 2022-04-12 → 2026-05-29 | AMLX Mar avg: -25.28% median: -12.05% win: 25% σ: 40.98% n: 4 2022-04-12 → 2026-05-29 | AMLX Apr avg: -1.69% median: -3.20% win: 40% σ: 32.85% n: 5 2022-04-12 → 2026-05-29 | AMLX May avg: -5.76% median: -4.97% win: 20% σ: 5.88% n: 5 2022-04-12 → 2026-05-29 | AMLX Jun avg: 34.74% median: 17.47% win: 75% σ: 56.71% n: 4 2022-04-12 → 2026-05-29 (current) | AMLX Jul avg: 20.64% median: 16.99% win: 100% σ: 15.20% n: 4 2022-04-12 → 2026-05-29 | AMLX Aug avg: 2.51% median: 0.64% win: 50% σ: 11.90% n: 4 2022-04-12 → 2026-05-29 | AMLX Sep avg: 21.82% median: 28.21% win: 75% σ: 29.33% n: 4 2022-04-12 → 2026-05-29 | AMLX Oct avg: 21.24% median: 14.61% win: 75% σ: 34.05% n: 4 2022-04-12 → 2026-05-29 | AMLX Nov avg: 1.13% median: 5.07% win: 75% σ: 9.82% n: 4 2022-04-12 → 2026-05-29 | AMLX Dec avg: -12.72% median: -11.53% win: 25% σ: 15.98% n: 4 2022-04-12 → 2026-05-29 |